PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Pneumococcal Vaccines”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1999

Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older.

The effectiveness of simultaneously administered influenza and pneumococcal vaccines vs. influenza vaccine alone in preventing pneumonia, pneumococcal pneumonia and pneumococcal bacteraemia among the elderly was studied. The vaccines were offered to all persons aged 65 years or older (N=43,500) living in 35 administrative districts in Northern Finland. A total of 26,925 persons (62%) decided to participate. Allocation to the vaccination groups took place by year of birth (odd/even). The total follow-up of those vaccinated consisted of 38,037 person years. The incremental effectiveness of the pneumococcal vaccine was -20 (95% CI -50- + 10%) for pneumonia, -20 (95% CI -90- + 20%) for pneumococcal pneumonia and + 60% (95% CI -40- +90%) for pneumococcal bacteraemia. Thus the pneumococcal polysaccharide vaccine did not offer any additional protection from pneumonia among elderly people in Finland although it reduced the incidence of bacteraemia.

Aged↗
PubMed2003

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.

BACKGROUND: Streptococcus pneumoniae is one of the main causes of bacterial meningitis, bacteremia, pneumonia, and otitis media in the Netherlands. These diseases lead to substantial mortality, morbidity, and costs. The societal impact is especially severe because most cases occur in very young infants. OBJECTIVE: The aim of this study was to estimate the epidemiological impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. METHODS: Decision analysis was performed using epidemiological data and data on health care resource use from 1996 to 2001. A model was used to project the impact of pneumococcal vaccination on the incidence of pneumococcal infections in infants and children from birth to age 10 years. Costs, benefits, and health gains were estimated, and cost-effectiveness was calculated. All analyses were performed from a societal perspective. RESULTS: On average, 339 cases per year of invasive pneumococcal infection occurred in infants and children from birth to age 10 years in the Netherlands from 1996 to 2001. The model predicted that introduction of the 7-valent conjugated pneumococcal vaccine would prevent 48 cases of bacterial meningitis and 88 cases of pneumococcal bacteremia per year, as well as 42,695 cases of pneumococcal otitis media and 3411 cases of invasive pneumococcal pneumonia. The model also predicted that vaccination would save 13 lives per year and prevent 31 cases of lifelong sequelae, rendering 382 discounted quality-adjusted life-years (QALYs) gained or 329 discounted life-years gained per year. Considering these health gains, vaccination would prevent Euro 9,453,600 of direct and indirect medical costs of meningococcal and pneumococcal infections in the Netherlands, including acute medical care, management of sequelae, and lost time at work. With a vaccine price of Euro 40 per dose, the base-case cost-effectiveness ratio would be Euro 71,250 per QALY. The model was sensitive to changes in incidence of infections, vaccine effectiveness, and vaccine price. CONCLUSIONS: Our analytic model predicted that universal pneumococcal vaccination of infants in the Netherlands could prevent a large number of pneumococcal infections and considerably reduce related mortality and morbidity. However, the baseline cost-effectiveness ratio of such a vaccination program would be relatively unfavorable compared with other interventions implemented in the Netherlands.

Cost-Benefit Analysis↗
PubMed2006

Nasopharyngeal colonization: a target for pneumococcal vaccination.

The pneumococcal conjugate vaccine (PCV), licensed in 2000, is highly efficient in preventing serious disease caused by serotypes in the vaccine and also prevents symptomless colonization of the nasopharynx. Prevention of this first step in the infection cycle has important consequences: it reduces chances of spread of the infection and indirectly protects from disease. Through these indirect effects, the protection afforded by the vaccine extends to the whole population, including those not vaccinated (herd immunity). Already now, after 5 years of wide use of PCV for infant immunization in the USA, more cases are prevented through the indirect effects than by vaccine-induced immunity in those vaccinated. The extended protection increases the cost-effectiveness of PCV and should clearly encourage its use in poorly resourced countries. However, the accumulated experience also shows that the herd immunity, due to PCV, is partly offset by replacement of the vaccine serotypes by other, nonvaccine serotypes. Owing to the general reduced virulence of the latter, this has only had a modest effect on disease, but the possibility of more virulent nonvaccine serotypes arising cannot be ignored and should be the focus of continued surveillance.

Animals↗
PubMed2003

Immunogenic protein contaminants in pneumococcal vaccines.

Currently available pneumococcal vaccines were examined for contamination by pneumococcal surface protein A (PspA) and pneumococcal surface adhesin A (PsaA). PspA could be detected in some (but not all) lots of 23-valent polysaccharide vaccine. Many lots of pneumococcal vaccines, including the heptavalent conjugate vaccine, were found to elicit small (but variable) antibody responses to PspA, PsaA, or both. The degree of contamination was highly variable, and this should be considered in pneumococcal vaccine evaluations or when capsular polysaccharide is used for pneumococcal antibody assays.

Adhesins, Bacterial↗
PubMed2005

Severe febrile systemic reaction to pneumococcal vaccine.

Polyvalent pneumococcal polysaccharide vaccine (Pneumovax, PPV) has been shown to substantially reduce the risk of Streptococcus pneumoniae infections in susceptible individuals. Side effects, such as mild local erythema, induration, pain and fever, have been reported with various frequencies. Rarely, systemic symptoms, including high fever, headache, nausea and photophobia, have been reported in the literature. This case report describes a 38-year-old male who developed severe and prolonged local and systemic symptoms necessitating hospitalization following a dose of pneumovax.

Acute Disease↗
PubMed2005

Pneumococcal vaccine efficacy for mucosal pneumococcal infections depends on Fcgamma receptor IIa polymorphism.

IgG2 antibodies are the main antibody subclass produced after pneumococcal polysaccharide vaccination. For these antibodies to be effective, interaction with FcgammaIIa receptors on phagocytic cells is necessary. FcgammaRIIa displays a functional polymorphism with either a histidine (H) or arginine (R) at position 131. Interaction of IgG2 antibodies depends on the H131 allele, whereas this interaction is low to absent with the R131 allele. We tested the clinical efficacy of combined pneumococcal conjugate and pneumococcal polysaccharide vaccination according to FcgammaIIa-H/R131 genotype in a randomized double blind placebo controlled vaccination trial in children with a history of acute otitis media. We found a decisive role for the FcgammaIIa-H/R131 polymorphism on the clinical vaccine efficacy of combined pneumococcal conjugate and polysaccharide vaccinations. RR homozygotes showed a significant increase in recurrence of acute otitis media after pneumococcal vaccinations. This cannot be explained by differences in the pneumococcal specific antibody response or differences in nasopharyngeal pneumococcal carriage, but may be explained by less efficient interaction of FcgammaRIIa with polysaccharide-induced IgG2 anti-pneumococcal antibodies in RR homozygotes. Our data show that the genetic make-up of individuals or populations under study should be considered while evaluating vaccine efficacy trials.

Alleles↗
PubMedDate not supplied

[Pneumococcal vaccine: overview about the protective efficacy in different high risk groups and new progress in the development of a conjugate pneumococcal vaccine].

The author presents a review about the protective efficacy of polyvalent pneumococcal polysaccharide vaccines in different groups at high risk for severe pneumococcal infection and the difficulties in the development of a conjugate pneumococcal vaccine capable of offering protection to younger children.

English Abstract↗
PubMed1994

Prevention of respiratory infections in adults. Influenza and pneumococcal vaccines.

Influenza and pneumococcal infections are important causes of hospitalization and death among individuals who are elderly or who have chronic illnesses. Influenza and pneumococcal vaccines may prevent these infections and their complications, but most high-risk patients have not received them. Doubts about their effectiveness, fears of side effects, and the lack of programs to promote their use contribute to the underuse of these vaccines. Although adequate controlled trials in high-risk patients are lacking, there is observational evidence that they are moderately effective, reducing serious complications of influenza and pneumococcal infections by about one-half. They are cost-effective compared with other preventive interventions and may be cost saving. Their safety has been demonstrated in numerous studies. Health care providers should promote influenza and pneumococcal vaccination. Strategies that have been shown to be successful in increasing the use of these vaccines include provider education and feedback, flagging charts of vaccination candidates, mailed reminders to patients without fall appointments, standing orders for nurses to administer the vaccines, walk-in vaccination clinics, and vaccination of hospitalized patients at discharge.

Bacterial Vaccines↗
PubMed2003

[Persistence of antibodies three years after vaccination with the 23-valent pneumococcal vaccine].

OBJECTIVE: To study the persistence of antibodies after primary immunization with the 23-valent pneumococcal vaccine in children with nephrotic syndrome. METHODS: Sera from 14 of 26 children with nephrotic syndrome were obtained 3 years after vaccination. We used an ELISA method to measure IgG antibody levels to pneumococcal serotypes 14, 23F, 3 and 6B. Antibody levels before vaccination, 1 month and 3 years after vaccination were compared. RESULTS: Significant increases in specific antibody concentrations were observed 30 days after vaccination for all serotypes except serotype 3. Differences in response according to serotype were found. The highest serological response was observed for serotype 14 (78.5 % of the patients showed a good-to-moderate response). Three years after vaccination antibody levels were significantly decreased (27.3 % of children for serotype 14, 46.2 % for serotype 23F and 50 % for serotype 6B). CONCLUSIONS: The 23-valent pneumococcal vaccine is immunogenic in children aged more than 2 years with nephrotic syndrome. Response varied according to serotype. Persistence of vaccine-induced antibodies is short-term, with low antibody levels 3 years after immunization. The results of this study suggest that these patients require revaccination 3 years after the first dose.

Antibodies, Bacterial↗
PubMed1981

Antibody response to group B streptococcus type III and AB blood group antigens induced by pneumococcal vaccine.

The effect of pneumococcal vaccination on antibodies to Streptococcus pneumoniae type 14, group B streptococcus type III, and AB blood group antigens was studied in 40 vaccinated adults. Fourfold or greater increases in type-specific IgG antibody to Pn-14 were found in 26 of 40 vaccines (mean increase 6.4-fold) and against GBS-III in 16 of the 40 (mean increase 2.9-fold) by an indirect immunofluorescence assay. However, only six of the 26 vaccinees with low levels (titers less than or equal to 20) of GBS-III antibody in prevaccination sera developed titers greater than 20 after vaccination. Thus, vaccination with polyvalent pneumococcal vaccine does not reliably induce high levels of IF antibody to GBS-III. Fourfold or greater increases in IgG isohemagglutinins against blood group A cells were also found in 22 of 27 vaccines (mean increase 4.5-fold) and against blood group B cells in nine of 34 (mean increase 1.7-fold) using the indirect anti-human globulin test. Chromatographic fractionation of selected sera confirmed that the anti-A isohemagglutinins stimulated in group O subjects were of the IgG class. Thus, pneumococcal vaccination during incompatible pregnancy could potentiate AO hemolytic disease of the newborn infant.

ABO Blood-Group System↗
PubMedDate not supplied

[The cost-effectiveness of pneumococcal vaccination in Catalonia].

BACKGROUND: Pneumococcal vaccine is an effective preventive measure against pneumococcal infections. Cost-effectiveness of pneumococcal vaccination of 5 or more years aged population of Catalonia has been evaluated in this study. METHODS: Cost-effectiveness has been estimated in terms of net cost per life-year gained (LYG) and net cost per quality adjusted life year gained (QALY). To calculate the net program cost, a cost of 1200 pesetas ($ 10) per individual has been assumed and averted disease cost in hospital and primary health care have been calculated. RESULTS: Pneumococcal vaccination could obtain 3,360 LYGs and 6,463 QALYs in the population of Catalonia. The program cost has been estimated at 2,800 million pesetas. Cost-effectiveness in million pesetas is 10.1 per LYG and 4.3 QALY in the age group from 5 to 24; 4.2 per LYG and 1.9 per QALY in the age group from 25 to 44; 1.0 per LYG and 0.5 per QALY in the age group from 45 to 44, and it is negative (benefits > costs) in the age group of 65 years old and over. CONCLUSIONS: Pneumococcal vaccination is cost-effective in individuals aged 65 or more, and has a favourable ratio in those aged from 45 to 64.

Adolescent↗
PubMedDate not supplied

Project protect: pneumococcal vaccination in Washington State nursing homes.

BACKGROUND: Pneumonia is the third most frequent cause of hospitalization among Medicare beneficiaries in Washington State. While a vaccine against pneumococcal disease has been available since 1977, the 1999 Behavioral Risk Factor Surveillance System estimates that less than 60% of adults aged 65 years and older in Washington State have been vaccinated. METHODS: To assess the prevalence of pneumococcal vaccination policies, we surveyed all Washington nursing homes in 1999 and again in 2001 to assess changes during the intervening period. Following the policy surveys, to estimate the pneumococcal vaccination rate, we conducted assessments of a random sample of residents of Washington nursing homes. RESULTS: Use of standing orders/written pneumococcal vaccination policies by nursing homes increased by 14% from 58% in 1999 to 72% in 2001. The pneumococcal vaccination rate for residents of nursing homes increased from 47% in 2000 to 61% in 2002. Both increases were statistically significant. The odds of a resident receiving a pneumococcal polysaccharide vaccine (PPV) in a nursing home having standing orders or other written guidelines are estimated to be two-and-a-half times greater than for residents in facilities without any PPV guidelines (2000: OR = 2.59; 95% CI, 1.54-4.34; 2002: OR = 3.19; 95% CI, 1.68-6.01). CONCLUSION: Increased use of standing orders/written policies has contributed to higher rates of pneumococcal vaccination in Washington State nursing homes.

Aged↗
PubMed2006

Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma.

Pneumococcal vaccination is advocated for asthmatics. Although routinely performed, data supplying evidence for this recommendation are limited. We examined the immunological background of 215 asthmatic children (2-5 year old) at a university children's hospital and compared the immunogenicity of the recommended pneumococcal vaccines. Testing encompassed serum immunoglobulins, immunoglobulin G (IgG)-subclasses, and pneumococcal antibodies against serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. An infection-prone subgroup received one dose of 23-valent pneumococcal polysaccharide vaccine (PPV-23; n = 38, median age 45 months) or of 7-valent conjugate vaccine (PCV-7; n = 23; median age 35 months). Pneumococcal antibodies were determined again after 4 weeks. Low immunoglobulin- and/or IgG-subclass levels were found in 27 subjects (14 infection-prone). Prevaccination pneumococcal antibody levels ranged from 0.36 to 1.06 microg/ml, depending on the serotype. The percentage of subjects with putative protective antibody levels > or =1.0 microg/ml ranged only from 19.9% to 54.1%, over all. Postvaccination, antibody geometric mean concentrations increased significantly higher in PCV-7 vaccinees for serotype 14 (p < 0.01) and 23F (p < 0.05). Now the percentage of putatively protected subjects ranged from 40.9% (serotype 6B) to 90.9% (serotype 19F) following PCV-7 compared with 31.6% (serotype 6B and 23F) to 81.6% (serotype 19F) in PPV-23 vaccinees. Our data give further evidence for pneumococcal vaccination of asthmatic children. PCV-7 is at least as immunogenic as PPV-23. Moreover, for children suffering from persistent asthma, PCV immunisation should be considered.

Antibodies, Bacterial↗
PubMed2003

Facilitating influenza and pneumococcal vaccination through standing orders programs.

Influenza and pneumococcal vaccines are underused for persons in the United States aged > or = 65 years (66% receive influenza vaccine and 55% pneumococcal vaccine), even among patients in nursing homes (68% for influenza and 38% for pneumococcal vaccine). Systematic literature reviews by the Task Force on Community Preventive Services and the Southern California Evidence-Based Practice Center-RAND have shown that standing orders programs improve vaccination rates. Standing orders programs authorize nurses and pharmacists, where allowed by state law, to administer vaccinations according to an institution- or physician-approved protocol without the need for a physician's examination or direct order. Several studies have shown improved influenza and pneumococcal vaccination rates through standing orders programs specifically in long-term care facilities (LTCFs) and hospitals. Based on the strength of available evidence, the Advisory Committee on Immunization Practices recommends the use of standing orders programs in both outpatient and inpatient settings.

Aged↗